Lilly Gets Second EUA, For Baricitinib In COVID-19 Patients
Executive Summary
Weeks after FDA authorized emergency use of its antibody bamlanivimab, Lilly’s RA drug Olumiant can be used to shorten recovery time for hospitalized COVID-19 patients in the US. Authorizations are being pursued elsewhere as well.
You may also be interested in...
Lilly Faces India IP Challenges From Natco For Verzenio, Olumiant
Lilly’s anticancer abemaciclib and rheumatoid arthritis drug baricitinib, which has received a US EUA for COVID-19, have become targets of challenger Natco in India. The US giant says it's working closely with India’s health ministry to ensure access to patients who need its innovative therapies, amid indications Natco may be weighing plans to seek a voluntary license for baricitinib.
Lilly’s 2021 Double-Digit Growth Comes From COVID-19 Drugs, New Products
Most of Lilly’s 2021 gains will come from its newer products, but sales of COVID-19 treatments added $500m to the company’s 2020 revenue guidance and may total $1bn-$2bn next year.
Positive Atopic Dermatitis Data On Lilly's Newly-Approved Olumiant
It has gone under the radar that Eli Lilly and Incyte's Olumiant has recently become the first JAK inhibitor to be approved anywhere for atopic dermatitis and the companies have been touting promising long-term data on the therapy as it expands beyond rheumatoid arthritis.
Need a specific report? 1000+ reports available
Buy Reports